Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
31
2023 to 2026
Breakthrough
4
Accelerated
1
Priority review
9
Orphan
8
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 5 | 1 |
| 2024 | 5 | 1 |
| 2025 | 6 | 4 |
| 2026 | 4 | 5 |
31 approvals
Newest first. Hover a badge for what it means.
- Sunharbo (Asundexian) · Bayer HealthcareNov 9, 2026
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack
- Onswik (Insulin Efsitora Alfa-Gobe) · Eli Lilly and COSep 23, 2026
To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise
- Garzulys (Insulin Aspart-Fsan) · Emerge Bioscience Pte. Ltd.Sep 15, 2026Original approval · BLA 761497Approval letter
- Garzulys (Insulin Aspart-Fsan) · Emerge Bioscience Pte. Ltd.Jul 24, 2026Original approval · BLA 761497Approval letter
- Lipfendra (Enlicitide Decanoate) · MsdJul 15, 2026
To reduce low-density lipoprotein cholesterol
- Baxfendy (Baxdrostat) · Astrazeneca AbMay 15, 2026
To treat hypertension in combination with other antihypertensive drugs
- Langlara (Insulin Glargine-Aldy) · Sunshine Lake Pharma CO LTDApr 29, 2026Original approval · BLA 761412Approval letter
- Foundayo (Orforglipron Calcium) · Eli Lilly and COApr 1, 2026
To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity
- Awiqli Flextouch (Insulin Icodec) · Novo Nordisk INCMar 26, 2026
- Yartemlea (Narsoplimab-Wuug) · Omeros CorpDec 23, 2025
To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy
- Myqorzo (Aficamten) · CytokineticsDec 19, 2025
To treat symptomatic obstructive hypertrophic cardiomyopathy
- Cardamyst (Etripamil) · Milestone Pharms USADec 12, 2025
To treat episodes of paroxysmal supraventricular tachycardia
- Lerochol (Lerodalcibep-Liga) · Lib Therapeutics, Inc.Dec 12, 2025
To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise
- Redemplo (Plozasiran Sodium) · ArrowheadNov 18, 2025
To reduce triglycerides in adults with familial chylomicronemia syndrome
- Wayrilz (Rilzabrutinib) · Genzyme CorpAug 29, 2025
To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids
- Kirsty (Insulin Aspart-Xjhz) · Biocon Biologics INCJul 15, 2025Original approval · BLA 761188Approval letter
- Widaplik (Amlodipine Besylate, Indapamide, Telmisartan) · AzurityJun 5, 2025Original approval · NDA 219423Approval letter
- Eliquis (Apixaban) · BristolApr 17, 2025
- Merilog (Insulin Aspart-Szjj) · Sanofi-Aventis U.S. LLCFeb 14, 2025Original approval · BLA 761325Approval letter
- Rapiblyk (Landiolol Hydrochloride) · Aop Hlth USNov 22, 2024
To treat supraventricular tachycardia
- Attruby (Acoramidis Hydrochloride) · Bridgebio PharmaNov 22, 2024
To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis
- Flyrcado (Flurpiridaz F-18) · Ge HlthcareSep 27, 2024
A radioactive diagnostic drug to evaluate for myocardial ischemia and infarction
- Entresto Sprinkle (Sacubitril, Valsartan) · NovartisApr 12, 2024Original approval · NDA 218591Approval letter
- Winrevair (Sotatercept-Csrk) · Merck Sharp DohmeMar 26, 2024
To treat pulmonary arterial hypertension
- Tryvio (Aprocitentan) · IdorsiaMar 19, 2024
To treat hypertension
- Zepbound (Tirzepatide) · Eli Lilly and CONov 8, 2023
- Inpefa (Sotagliflozin) · Lexicon Pharms INCMay 26, 2023
To treat heart failure
- Elfabrio (Pegunigalsidase Alfa-Iwxj) · Chiesi Farmaceutici SpaMay 9, 2023
To treat confirmed Fabry disease
- Filspari (Sparsentan) · TravereFeb 17, 2023
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
- Atorvaliq (Atorvastatin Calcium) · Cmp Dev LLCFeb 1, 2023Original approval · NDA 213260Approval letter
- Brenzavvy (Bexagliflozin) · TheracosbioJan 20, 2023
To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.